The following video Q&A; captures interviews we conducted with several physicians who are investigators in Opexa’s Tovaxin clinical trials to share their thoughts about multiple sclerosis, the current treatment landscape and Tovaxin, our T-cell therapy in clinical development. The biographies of the participants are included below.

Click on a question to watch a short video of the clinical investigators’ responses.

Tovaxin Q & A

Please click the questions to watch the video responses.


The statements made by the physicians in this video, including any statements regarding various drugs and treatments, are their personal opinions and observations and are not the opinions or statements of their respective institutions or of Opexa Therapeutics, Inc. Further, the statements in the video should not be considered medical advice and you should consult your own qualified healthcare provider regarding any questions or concerns you may have about your health or about the potential beneficial uses and possible adverse effects of any healthcare product.

The information discussed related to our product candidate is preliminary and investigative. Such product candidate is not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidate. Only the FDA can determine whether the product candidate is safe and effective for the use(s) being investigated.

Statements contained in this video, other than statements of historical fact, constitute “forward-looking statements.” The words “expects,” “believes,” “anticipates,” “estimates,” “may,” “could,” “intends,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements do not constitute guarantees of future performance. Investors are cautioned that statements which are not strictly historical statements, including, without limitation, statements regarding current or future financial payments, returns, royalties, performance and position, management’s strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance, and management’s initiatives and strategies, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: market conditions, Opexa’s capital position, the ability of Opexa to enter into and benefit from a partnering arrangement for Opexa’s product candidate, Tovaxin®, on reasonably satisfactory terms (if at all), Opexa’s dependence (if partnered) on the resources and abilities of any partner for the further development of Tovaxin, Opexa’s ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of diseases Opexa targets, Opexa’s expectation of incurring continued losses, Opexa’s uncertainty of developing a marketable product, Opexa’s ability to raise additional capital to continue its development programs, the success of Opexa’s clinical trials, Opexa’s ability to develop and commercialize products, Opexa’s ability to obtain required regulatory approvals, Opexa’s compliance with Food and Drug Administration regulations, Opexa’s ability to obtain, maintain and protect intellectual property rights (including for Tovaxin), the risk of litigation regarding Opexa’s intellectual property rights, the success of third party development and commercialization efforts with respect to products covered by intellectual property rights transferred by Opexa, Opexa’s limited manufacturing capabilities, Opexa’s dependence on third-party manufacturers, Opexa’s ability to hire and retain skilled personnel, Opexa’s volatile stock price, and other risks detailed in Opexa’s filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date made. Opexa assumes no obligation or undertaking to update or revise any forward-looking statements to reflect any changes in expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based. You should, however, review additional disclosures Opexa makes in the reports filed with the Securities and Exchange Commission.